About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The goal of the Shock, Organic Dysfunction and Resuscitation Research Group (SODIR) is comprehensive, innovative research into the areas of shock, acute respiratory failure, acute kidney failure, organic dysfunction, resuscitation and critical patient monitoring. In addition, the research group has a special interest in applying artificial intelligence as an instrument to find innovative solutions for critical patients.
PMID: 33856256 Journal: JOURNAL OF APPLIED PHYSIOLOGY Year: 2021 Reference: J Appl Physiol (1985). 2021 Jun 1;130(6):1660-1667. doi: 10.1152/japplphysiol.00614.2020. Epub 2021 Apr 15. Impact factor: 3.532 Publication type: Paper in international publication Authors: Garcia de Acilu, Marina, Pacheco, Andres, Santafe, Manel, Ramos, Francisco-Javier, Ruiz-Rodriguez, Juan C, Ferrer, Ricard, Roca, Oriol et al. DOI: 10.1152/japplphysiol.00614.2020
PMID: 33805755 Journal: Antibiotics-Basel Year: 2021 Reference: Antibiotics (Basel). 2021 Mar 13;10(3). pii: antibiotics10030299. doi: 10.3390/antibiotics10030299. Impact factor: 4.639 Publication type: Paper in international publication Authors: Krzanowski, Marcin, Czepiel, Jacek, Krutova, Marcela, Mizrahi, Assaf, Khanafer, Nagham, Enoch, David A, Patyi, Marta, Deptula, Aleksander, Agodi, Antonella, Nuvials, Xavier et al. DOI: 10.3390/antibiotics10030299
PMID: 33810263 Journal: Antibiotics-Basel Year: 2021 Reference: Antibiotics (Basel). 2021 Mar 26;10(4). pii: antibiotics10040350. doi: 10.3390/antibiotics10040350. Impact factor: 4.639 Publication type: Paper in international publication Authors: Carbonell, Raquel, Moreno, Gerard, Martin-Loeches, Ignacio, Gomez-Bertomeu, Frederic, Sarvise, Carolina, Gomez, Josep, Bodi, Maria, Diaz, Emili, Papiol, Elisabeth, Trefler, Sandra et al. DOI: 10.3390/antibiotics10040350
PMID: 33813139 Journal: EBioMedicine Year: 2021 Reference: EBioMedicine. 2021 Apr;66:103291. doi: 10.1016/j.ebiom.2021.103291. Epub 2021 Apr 1. Impact factor: 8.143 Publication type: Review in international publication Authors: Skirecki, Tomasz, Brunkhorst, Frank M, Cajander, Sara, Cavaillon, Jean-Marc, Ferrer, Ricard, Flohe, Stefanie B, Garcia-Salido, Alberto, Giamarellos-Bourboulis, Evangelos J, Girardis, Massimo, Kox, Matthijs et al. DOI: 10.1016/j.ebiom.2021.103291
The study will be conducted in the Intensive Care Medicine Service of the Vall d’Hebron University Hospital and will validate the prognostic value of the NLRP3 biomarker.
SOFA-2 is being updated after thirty years to incorporate advances in diagnosis, monitoring and life support.
On European Antibiotic Awareness Day, we highlight the importance of using these medications responsibly and finding innovative solutions to combat this issue.
